Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac

Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents

“…The ELISA protocol was modified from Amanat et al [20] and performed as described previously [21] , [22] . Briefly, the ELISA plates were coated with purified recombinant Myc-His-tagged S-RBD, residues 319-541 from SARS-CoV-2 (Wuhan-Hu-1).…”

“…The surrogate virus neutralization test was adjusted from Tan et al (2020) [23] and performed as described previously [21] , [22] , utilizing the HRP-tagged recombinant SRBD from the wild-type (Wuhan-Hu-1), Delta (B.1.617.2), and Omicron (B.1.1.529 – BA.1) strains. The 96-well plates coated with 0.1 µg/well purified recombinant human ACE2 ectodomain were used to incubate with serum samples (at 1:10 dilution) - SRBD mixture.…”

Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru

“…Other studies evaluating mRNA/inactivated virus vaccine match presented lower measurements than ours. Chad booster following full CV regimes after two weeks reached 873.9-2037.1 BAU/mL [33] , [42] , [43] . A greater immune response was also observed compared to two-dose CV vaccinees boosted with BNT [4] , [22] , [44] , [45] .…”